Your session is about to expire
← Back to Search
Vandetanib for Thyroid Cancer
Study Summary
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 2 trial • 95 Patients • NCT00659438Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major surgery in the last 4 weeks.My brain or spinal metastases have been treated and stable for 4 weeks without steroids for 10 days.I have been treated with ZD6474 before.My thyroid cancer cannot be removed by surgery and has spread.My tumor can be measured.I haven't had radiation therapy in the last 4 weeks, except for palliative care.I received my last chemotherapy dose less than 4 weeks ago.I have had major heart problems.I can swallow pills.
- Group 1: 1
- Group 2: 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are participating in this clinical trial?
"Unfortunately, this study is no longer enrolling patients. The trial was initially posted on 2006-11-30 and was last updated on 2022-10-03. However, there are other ongoing trials that may be of interest. There are 306 clinical studies currently recruiting patients with carcinoma and neuroendocrine cancers. Additionally, there are 12 ZD6474 (Vandetanib) trials looking for participants."
Are there any current openings for participants in this research project?
"This study has completed recruitment for volunteers. The trial was first posted on 11/30/2006 and was last edited on 10/3/2022. However, there are other ongoing studies which might be of interest. As of now, 306 trials are actively enrolling participants with carcinoma, neuroendocrine and 12 trials for ZD6474 (Vandetanib) are admitting patients."
To your knowledge, is this the first time this type of trial has been conducted?
"As of now, there are 12 ongoing clinical trials for the drug ZD6474 (Vandetanib) in 153 cities and 42 countries. The first trial for this medication was held back in 2006. That initial study, which was sponsored by Genzyme (a Sanofi Company), involved 437 patients and completed its Phase 3 drug approval stage. In the 14 years since 2006, an additional 57 trials have been conducted."
What is the most recent decision by the FDA concerning ZD6474 (Vandetanib)?
"ZD6474 (Vandetanib) has been deemed safe by our team at Power, who gave it a score of 3. This is due to the fact that this Phase 3 trial has shown some efficacy in past patients, as well as multiple rounds of supportive data."
What are some other circumstances in which ZD6474 (Vandetanib) has been tested?
"ZD6474 (Vandetanib) was first studied in 2006 at site number 2. Since then, there have been 57 completed trials with 12 ongoing studies. Many of the active clinical trials are being conducted out of Detroit, Michigan."
By how many different organizations is this research project being overseen?
"If you're looking to enroll in this study, know that there are 21 different recruitment sites. These locations include Detroit, Houston, Calgary and 18 additional cities. To cut down on travel, try and choose the site closest to your residence."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger